
MiNK Therapeutics (INKT) Stock Forecast & Price Target
MiNK Therapeutics (INKT) Analyst Ratings
Bulls say
MiNK Therapeutics is attractive fundamentally because its lead asset, agenT-797, targets ARDS—a fatal ICU condition with no FDA-approved pharmacological therapy—using a single off-the-shelf iNKT infusion that is logistically practical, HLA-independent, and does not require lymphodepletion. Early Phase 1/2 data showed 70% 30-day survival in 21 ventilated COVID-19 ARDS patients versus about 10% in contemporaneous controls, with no CRS or ICANS reported, while the ongoing randomized Phase 2b/3 could validate these signals and support a registrational path. Beyond ARDS, the company has additional optionality from oncology and engineered iNKT programs, plus non-dilutive support for military medicine and transplantation work, all of which enhances the long-term upside without being fully reflected in current valuation.
Bears say
MiNK Therapeutics is viewed negatively because its lead asset, agenT-797, faces substantial clinical, regulatory, and commercial uncertainty, including unproven regulatory precedent for iNKT cell therapy and the possibility that the FDA may not accept the seamless Ph2b/3 design as registrational. The company’s latest reported cash and cash equivalents were only $8.8 million as of June 30, 2026, which suggests it will likely need additional capital within the next 12 months and may resort to dilutive equity financing before reaching profitability. Even if development succeeds, adoption, pricing, and reimbursement remain unclear in a crowded treatment landscape, leaving limited confidence that future revenues will offset ongoing development and commercialization costs.
This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
MiNK Therapeutics (INKT) Analyst Forecast & Price Prediction
Start investing in MiNK Therapeutics (INKT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About MiNK Therapeutics (INKT) Forecast
MiNK Therapeutics (INKT) Analyst Forecast & Price Prediction
Start investing in MiNK Therapeutics (INKT)
Order type
Buy in
Order amount
Est. shares
0 shares